BioSpace News Archive

PXL065 observed to have a favorable safety, tolerability and pharmacokinetic (PK) profile in the Phase 1a trial

Fennec Pharmaceuticals Inc. reported its business update and financial results for the third quarter ended September 30, 2019.

Total Net Revenue (“Revenue”) increased 20.9% to $292.7 million in the third quarter of 2019 from $242.1 million in the third quarter of 2018

Company to provide update on status of ongoing Phase 2 clinical trial in eosinophilic asthma

Brand new innovation for inline measurement of inner diameter

In2Bones Global, Inc. announces the commercial launch of the CoLink® Mini Plating System, a comprehensive, minimally invasive anatomic compression plating system used for fractures and fusions in the small bones of the foot..

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce its lead product candidate, Bria-IMT™, will be featured in two poster sessions during the 2019 San Antonio Breast Cancer Symposium® taking place December 10-14 in San Antonio, Texas.

Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported financial results and corporate highlights for the third quarter of 2019.

Enrollment completed in SAGE-217 Phase 3 MOUNTAIN and SHORELINE studies with topline data expected in 4Q 2019 and 2020, respectively

Eagle Pharmaceuticals, Inc. provided an update on the Company’s program for RYANODEX® for the treatment of exertional heat stroke Eagle is investigating RYANODEX for EHS in addition to current standard of care, which is comprised of body cooling and supportive measures.